Press Releases - Emmaus Medical, Inc.

Emmaus Life Sciences Presents Positive Transfusion Data from a Post-Hoc Analysis of its Phase 3 Clinical Study of Endari® in Patients With Sickle Cell Disease at the 63rd American Society of Hematology (ASH) Annual MeetingDecember 14, 2021

Analysis Indicates that Patients Requiring Blood Transfusions and Receiving Endari Required ~43% Fewer Units of Red Blood Cells

Emmaus Life Sciences to Webcast Live at Life Sciences Investor Forum on December 16thDecember 09, 2021

Emmaus invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

Emmaus Life Sciences' Data on Endari Accepted for Poster Presentation at the 63rd American Society of Hematology Annual Meeting & ExhibitionDecember 07, 2021

Emmaus Life Sciences, Inc. today announced that data on Endari® has been accepted for a poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exhibition.

Emmaus Life Sciences Reports Third Quarter Financial Results and Business HighlightsNovember 12, 2021

Emmaus Life Sciences, Inc. today reported financial results for the quarter and nine months ended September 30, 2021.

Emmaus Life Sciences Announces Partnership with UpScript to Provide Telehealth Solutions to Sickle Cell Disease PatientsNovember 11, 2021

Emmaus Life Sciences, Inc. today announced a partnership with UpScript IP Holdings, LLC. (UpScript), to offer telehealth solutions to sickle cell disease patients, expanding access to Endari®, Emmaus’ prescription L-glutamine oral powder for the treatment of sickle cell disease.